Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 5/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2110073 | 1.00 | CYP3A4 (0.54) | CYP3A4CRBNCYP17A1GSK3BF10 | |
| SCHEMBL12990815 | 0.90 | CRBN (0.44) | CYP3A4CRBNCYP17A1PTGS1PTGS2 | |
| SCHEMBL12991328 | 0.89 | CRBN (0.44) | CYP3A4CRBNCYP17A1FLT3TP53 | |
| SCHEMBL2712730 | 0.88 | CYP3A4 (0.55) | CYP3A4CRBNCYP17A1GSK3BCYP24A1 | |
| SCHEMBL2618810 | 0.88 | CYP3A4 (0.55) | CYP3A4CRBNCYP17A1GSK3BCYP24A1 | |
| SCHEMBL2112193 | 0.87 | CRBN (0.42) | CYP3A4CRBNCYP17A1F10FLT3 | |
| SCHEMBL2111470 | 0.87 | CRBN (0.42) | CYP3A4CRBNCYP17A1F10TP53 | |
| SCHEMBL2111469 | 0.87 | CRBN (0.42) | CYP3A4CRBNCYP17A1F10TP53 | |
| SCHEMBL2111467 | 0.87 | CRBN (0.42) | CYP3A4CRBNCYP17A1F10FLT3 | |
| SCHEMBL2112194 | 0.87 | CRBN (0.42) | CYP3A4CRBNCYP17A1F10FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158631-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-04-17 | — | — | US | claimed |
| US-20100330032-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | CHIN ELBERT | 2010-12-30 | — | — | US | claimed |
| US-8158631-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-04-17 | — | — | US | disclosed |
| US-20100330032-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | CHIN ELBERT | 2010-12-30 | — | — | US | disclosed |
| WO-2010149598-A2 | HETEROCYCLIC ANTIVIRAL COMPOUND | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100330032-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, HCCS, RTF2 | CYP3A4 305/4885CRBN 2969/4885CYP17A1 2529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.